type 2 diabetes
Conditions
Interventions
Experimental Group:Insulin / metformin + acarbose chewable tablets
Control group:Insulin / metformin
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Type 2 diabetic patients, aged 18-80 years, 19 =20 IU/d and =1500 mg/day or reaching the maximum tolerable dose of individuals) for 2 weeks; use of other hypoglycemic drugs, can be included in the group after half a year of washout period; HbA1c 3.7 to 11%; 4. Volunteer to participate in the clinical study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who are allergic to acarbose and / or non active ingredients, biguanides or have severe allergic diseases; 2. Patients who had abdominal operation within two months; 3. Chronic gastrointestinal dysfunction patients with obvious digestive and absorption disorders; 4. Patients with diseases that may worsen due to flatulence (such as roemheld syndrome, severe hernia, intestinal obstruction and intestinal ulcer); 5. Serious impairment of heart, liver and kidney function (heart function level 3-4, ALT and / or ast more than 2.5 times of the upper limit of normal, creatinine clearance rate < 25ml / min); 6. Severe cardiovascular and cerebrovascular diseases in the past six months; 7. Patients with severe diabetes who need to be combined with other hypoglycemic drugs (random blood glucose is greater than 18 mmol/L); 8. Patients with malignant tumor and hematopathy; 9. Patients with chronic infectious diseases, collagen system diseases and other diseases that affect the results of the study; 10. Pregnant and lactating women, women of childbearing age do not agree to take contraceptive measures during the experiment; 11. Have mental disorders, cognitive disorders, etc. can not cooperate well; 12. Those who have participated in clinical trials of other drugs within three months; 13. Other conditions that the researchers think are not suitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1C;Blood glucose fluctuation; | — |
Secondary
| Measure | Time frame |
|---|---|
| FPG, PPG;Blood lipid profile;Daily dose of insulin;Changes in weight and waistline;Incidence of hypoglycemia;Incidence of adverse reactions in digestive tract; | — |
Countries
China
Contacts
Public ContactGuijun Qin
the First Affiliated Hospital of Zhengzhou University
Outcome results
None listed